Safety of immune checkpoint inhibitors: An updated comprehensive disproportionality analysis and meta-analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety of immune checkpoint inhibitors: An updated comprehensive disproportionality analysis and meta-analysis

Published:2024-08 Issue: Volume:200 Page:104398
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Tyagi Simran,Kumar Anoop^ORCID

Publisher

Elsevier BV

Reference44 articles.

1. Quantitative signal detection using spontaneous ADR reporting;Bate;Pharmacoepidemiol. Drug Saf.,2009

2. Pembrolizumab as second-line therapy for advanced urothelial carcinoma;Bellmunt;N. Engl. J. Med.,2017

3. OpenVigil FDA – Inspection of U.S. American Adverse Drug Events Pharmacovigilance Data and Novel Clinical Applications;Böhm;PLoS One,2016

4. Disproportionality analysis for pharmacovigilance signal detection in small databases or subsets: recommendations for limiting false-positive associations;Caster;Drug Saf.,2020

5. Pembrolizumab associated sarcoid-like lymphadenopathy mimicking progressive disease in Hodgkin lymphoma;Chau;Pathology,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP